Announcements Trials
Browse Landscape

Phase

Phase 2 32Phase 1 13Phase NA 7Phase 3 7Phase 1/2 4Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 276Neoplasms 202Prostatic Neoplasms 118Polycystic Ovary Syndrome 114Colorectal Neoplasms 103Carcinoma, Hepatocellular 103Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 70Stomach Neoplasms 62Precursor Cell Lymphoblastic Leukemia-Lymphoma 60Pain 59Neoplasm Metastasis 54Multiple Myeloma 52Pancreatic Neoplasms 46Keratosis, Actinic 46Head and Neck Neoplasms 43Pain, Postoperative 42Leukemia, Myeloid, Acute 40Leiomyoma 39Recurrence 38Liver Neoplasms 38Colonic Neoplasms 37Uterine Cervical Neoplasms 35Lymphoma 35Brain Neoplasms 34Infertility 33Papillomavirus Infections 32Ovarian Neoplasms 31Lymphoma, Follicular 31Lymphoma, Non-Hodgkin 30

Interventions

pembrolizumab 1enfortumab vedotin 1Specimen Handling 1Nephroureterectomy 1Magnetic Resonance Spectroscopy 1Hyperthermia, Induced 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Interventional × Ureteral Neoplasms × Clear all
NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Mayo Clinic

Phase 4 Recruiting
75 enrolled
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡